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WHAT THIS PAPER ADDS
 Vascular surgery patients are at increased risk of cardiac complications, due to underlying coronary artery disease. General
anaesthesia and epidural or local anaesthesia differ regarding the physical stress response evoked by surgery. It is unclear whether
or not this inﬂuences the risk of adverse cardiac events. This is the ﬁrst study evaluating the impact of anaesthesia type on cardiac
outcome after endovascular aneurysm repair (EVAR), to adjust for baseline differences between patients receiving different
anaesthesia techniques.a r t i c l e i n f o
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Objectives: Endovascular aneurysm repair (EVAR) is associated with reduced cardiac stress compared
with open repair and is an attractive therapeutic option, especially in cardiac fragile patients. General and
locoregional anaesthesia differ regarding the stress response evoked by surgery. The aim of the study is
to compare the incidence of cardiac events after EVAR under general or locoregional anaesthesia.
Methods: A total of 302 consecutive patients undergoing infrarenal EVAR between 2002 and 2011 were
analysed in this retrospective cohort study. Selection of anaesthesia typewas at the discretion of the treating
physicians. Medical history, medication use, anaesthesia technique and follow-upwere obtained. The study
end point was 30-day cardiac complications, including cardiac death, non-fatal myocardial infarction, heart
failure, ventricular arrhythmia and troponin T release. Multivariable analysis, adjusted for the propensity of
receiving a locoregional technique and cardiac risk factors according to the Revised Cardiac Risk Index, was
used to assess the association between cardiac events and anaesthesia type.
Results: A total of 173 patients underwent general anaesthesia and 129 locoregional anaesthesia. Obesity,
aspirin use and therapeutic anticoagulation were more common in patients receiving general anaes-
thesia. Cardiac events were observed in 13.3% of patients receiving general anaesthesia and in 4.7% of
patients receiving locoregional anaesthesia (P ¼ 0.02), or 6.4% versus .8% (P ¼ 0.02) when asymptomatic
troponin release is excluded from the end point. In the general anaesthesia group, two cardiac deaths, six
non-fatal myocardial infarctions, two cases of non-fatal heart failure, one non-fatal cardiac arrest and 12
cases of troponin T release were observed, compared with one myocardial infarction and ﬁve cases of
troponin T release in the locoregional anaesthesia group. In multivariable analysis, general anaesthesia
was associated with adverse cardiac events (odds ratio (OR) 3.8; 95%-conﬁdence interval (CI) 1.1e12.9).
Non-cardiac complications occurred in 11.6% of patients in both groups (P ¼ 1.00).
Conclusion: General anaesthesia was associated with an increased risk of cardiac events in EVAR,
compared with locoregional anaesthesia.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.-810, Erasmus MC, P.O. Box
31 10 7031810; fax: þ31 10
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crinologic stress reaction, blood loss and postoperative pain.
Subsequently, EVAR is associated with a reduced risk of cardiac
complications (3.1% vs. 21.8%), pulmonary complications and peri-
procedural mortality (1.7% vs. 4.7%), as compared with conven-
tional open aneurysm repair.2e6 EVAR is therefore an attractive
treatment strategy, especially in the more frail patients requiring
aneurysm repair.
Cardiac complications are a major cause of morbidity and
mortality following non-cardiac surgery, most importantly
myocardial infarction. The increased risk of myocardial infarction,
through either prolonged myocardial oxygen supply-to-demand
mismatch or coronary plaque rupture, is thought to arise from
the stress response evoked by the surgical procedure.7 The various
types of anaesthesia attenuate the surgical stress response to
a different extent. Differences in postoperative cardiac event rates
between anaesthesia types have been demonstrated previously.8
The performance of EVAR procedures was demonstrated to be
feasible under multiple types of anaesthesia, including general,
epidural, spinal and local anaesthesia.9 However, no conclusive
data exist on anaesthesia type and cardiac outcome in EVAR. The
aim of the current study is to assess the association between
anaesthesia type and cardiac events after EVAR procedure.
Materials and Methods
A total of 302 consecutive patients undergoing infrarenal EVAR
between 2002 and 2011 were analysed in this retrospective cohort
study. Emergency procedures were excluded, as were hybrid
procedures. The study was performed at a single site at the
Department of Vascular Surgery of the Erasmus Medical Center,
Rotterdam, the Netherlands. The study complies with the declara-
tion of Helsinki and was approved by the Institutional Review
Board.
Baseline characteristics
A detailed medical history was obtained from all patients prior
to surgery, with the emphasis on cardiovascular history and risk
factors. Congestive heart failure was deﬁned as a history of
congestive heart failure or the presence of S3 gallop or rales at both
bases during physical examination. Ischaemic heart disease was
deﬁned as a history of myocardial infarction, evidence of prior
myocardial infarction on an electrocardiogram or echocardiogram.
Additional clinical data included age, gender, diabetes mellitus,
renal dysfunction (creatinine > 2 mg dl1), hypertension (systolic
blood pressure140mmHg, diastolic blood pressure90mmHg in
non-diabetics, systolic blood pressure 130 mmHg, diastolic blood
pressure 80 mmHg in diabetics or the use of anti-hypertensive
drugs), cerebrovascular disease (history of stroke or transient
ischaemic attack), smoking status, body mass index (BMI) and
chronic obstructive pulmonary disease (according to the Global
Initiative on Obstructive Lung Diseases), and the presence of aortic
valve stenosis (ﬂow velocity over the aortic valve >2.5 m s1). In
addition, the use of beta-blockers, statins, aspirin, clopidogrel, oral
anti-coagulants, angiotensin-converting enzyme inhibitors, angio-
tensin receptor blockers, calcium channel blockers, diuretics and
nitrates was recorded.
Antiplatelet, anticoagulant and thromboprophylaxis policy
Chronic aspirin therapy is routinely continued perioperatively.
The decision whether or not to interrupt vitamin K antagonist
therapy and to initiate bridging therapy with heparin or low-
molecular-weight heparin (LMWH) was made on a case-to-casebasis. As per hospital protocol, thromboprophylaxis is routinely
initiated the night prior to surgery using prophylactic doses of
LMWH in patients not receiving therapeutic doses of LMWH or oral
anticoagulants. The preoperative dose is administered >12 h prior
to surgery.
Anaesthesia type
Selection of anaesthesia type was made on a case-to-case basis,
reﬂecting the anaesthesiologists, surgeons and patients consider-
ations. Of all patients, anaesthesia charts were examined for the
type of anaesthesia used, including general, epidural and local
anaesthesia. Anaesthesia type was categorised as either general or
locoregional. Adjuvant sedation in patients undergoing epidural or
local techniques without need of mechanical ventilation was not
scored as general anaesthesia.
Cardiac outcome
Serial electrocardiograms and troponin T measurements were
routinely obtained prior to surgery and on postoperative days 1, 3
and 7, unless discharged earlier, and whenever clinically indicated.
Troponin T was measured using the TropT version 2 assay from
Roche Diagnostics, Mannheim, Germany. The study end point is 30-
day adverse cardiac events, a composite of cardiovascular mortality,
non-fatal myocardial infarction, new or worsened congestive heart
failure, new arrhythmias (requiring immediate cardioversion,
cardiopulmonary resuscitation or pacing) and troponin T release.
Also, 30-day ‘major’ cardiac events are reported, a composite of
cardiac death, non-fatal myocardial infarction, new or worsened
congestive heart failure and new arrhythmias, but not including
troponin T release. Cardiovascular death was deﬁned as any death
from cardiovascular cause, including death following myocardial
infarction, congestive heart failure, arrhythmia and surgery-related
bleeding complications, or sudden unexpected death. Myocardial
infarction was deﬁned as postoperative classic rise and fall of
troponin T levels above the 99th percentile, with either electro-
cardiographic or clinical signs of myocardial ischaemia. Troponin T
release was deﬁned as at least one troponin T value above the 99th
percentile in the absence of electrocardiographic and clinical signs
of myocardial ischaemia and in the absence of other cardiac
complications. Patients were routinely scheduled for a follow-up
visit 30 days after surgery. In patients still admitted or read-
mitted, follow-up was completed using medical records. Cause of
death was ascertained by reviewing medical records or death
certiﬁcates.
Non-cardiac outcome
We report major pulmonary, renal, cerebrovascular, urological
and infectious complications requiring intervention, as well as all
surgical procedures for bleeding and device failure complications
required within 30 days of the initial EVAR procedure. Length of
hospital stay (in days) after EVAR procedure is reported.
Statistical analysis
Dichotomous data are presented as numbers and percentages.
Continuous data are presented as means  standard deviation.
Dichotomous data were compared using Chi-Square tests, contin-
uous data were compared using analysis of variance (ANOVA) or
ManneWhitney U tests as appropriate. Univariable and multivari-
able logistic regression models were used to assess the association
between anaesthesia type (general vs. locoregional) and 30-day
cardiac events. The following factors were considered as possible
Table 1
Baseline characteristics according to anaesthesia type.
General
(n ¼ 173)
Locoregional
(n ¼ 129)
P-value
Demographics
Mean age (SD) 72 (8) 72 (8) .75
Male gender (%) 155 (90) 120 (93) .42
Medical history (%)
Congestive heart failure 16 (9) 21 (16) .08
Cerebrovascular disease 28 (16) 15 (12) .32
Hypertension 122 (71) 75 (58) .03
Hypercholesterolaemia 162 (94) 112 (87) .05
Diabetes mellitus 44 (25) 22 (17) .09
Current smoking 77 (45) 52 (40) .48
Serum creatinin >2 mg/dL 25 (15) 26 (20) .22
Ischaemic heart disease 74 (43) 64 (50) .25
Aortic valve stenosis 6 (4) 3 (3) .74
COPD 81 (47) 51 (41) .29
BMI > 30 41 (24) 12 (9) <.01
Risk indices (SD)
Revised cardiac risk index 1.9 (1.0) 2.0 (1.0) .25
ASA class 2.5 (.6) 2.5 (.5) .59
Medication use (%)
Anticoagulants 29 (17) 17 (13) .42
Continuated perioperatively 12 (7) 3 (2) .11
Aspirin 125 (73) 63 (49) <.01
Clopidogrel 11 (6) 6 (5) .62
Abbreviatons: SD standard deviation; LVEF left ventricular ejection fraction; COPD
chronic obstructive pulmonary disease; BMI body mass index.
Table 2
30-day cardiac complications.
General
(n ¼ 173)
Locoregional
(n ¼ 129)
P-value
n (%) n (%)
Cardiac events
Cardiac death 2 (1.2) 0 (0) .51
Myocardial infarction 6 (3.4) 1 (.8) .25
Congestive heart failure 2 (1.2) 0 (0) .51
Arrhythmia 1 (.6) 0 (0) 1.00
Troponin release 12 (6.9) 5 (3.9) .32
Composite cardiac endpoints
All cardiac events 23 (13.3) 6 (4.7) .02
All but troponin release 11 (6.4) 1 (.8) .02
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mic heart disease, preoperative creatinine, preoperative haemo-
globin, chronic obstructive pulmonary disease, diabetes mellitus,
prior stroke, aortic valve stenosis, obesity (BMI > 30), the use of
beta-blockers, statins, aspirin, clopidogrel, oral anti-coagulants,
therapeutic anticoagulation at the time of surgery, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
calcium channel blockers, diuretics and nitrates. All possible
confounders were included in a multivariable logistic regression
model to compute a propensity score for the likelihood of receiving
locoregional versus general anaesthesia. To assess the association
between anaesthesia type and cardiac outcome, a multivariable
logistic regression model was applied. The Revised Cardiac Risk
score and propensity score were entered as co-variables. A two-
sided P-value of <.05 was considered signiﬁcant for all tests. All
analyses were performed using PASW version 17.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Of the 302 patients enrolled, general anaesthesia was applied in
173 (57%) patients, and locoregional anaesthesia in 129 (43%)
patients, including 78 (26%) cases of epidural and 51 (17%) cases of
local anaesthesia.
Baseline characteristics
General anaesthesia and locoregional anaesthesia groups
differed signiﬁcantly regarding the presence of hypertension (71%
vs. 58%, P¼ 0.03) and hypercholesterolaemia (94% vs. 87%, P¼ 0.05).
Obesity was more common in patients receiving general anaes-
thesia (24% vs. 9%, P < 0.01). Other co-morbid conditions, age and
gender were well balanced between both groups. General anaes-
thesia patients were more frequently treated with aspirin (73%
vs. 49%, P < 0.01). Surgery was performed under therapeutic anti-
coagulation (continuation of oral anticoagulants with an Interna-
tional Normalised Ratio >1.8 or bridging therapy with heparin or
LMWH in therapeutic doses) in 7% of general anaesthesia patients
and 2% of locoregional anaesthesia patients (P ¼ 0.11). No differ-
ences regarding clopidogrel usewere observed (6% vs. 5%, P¼ 0.62).
Baseline characteristics are presented in Table 1.
Length of stay
Themedian interquartile (IQR) length of hospital stay after EVAR
procedure was 3 (2e4) days in the general anaesthesia group and 2
(2e4) days in the locoregional anaesthesia group (P < 0.01).
Thirty-day mortality
In the perioperative period, four (1.3%) deaths were observed, all
of which occurred in the general anaesthesia group (P ¼ 0.14).
Thirty-day cardiac events
A total of 29 (9.6%) patients suffered a cardiac event within 30
days of surgery, including two cases of cardiac death, seven
myocardial infarctions, two cases of new congestive heart failure,
one cardiac arrest and 17 cases of asymptomatic Troponin T release.
All cases of myocardial infarction and heart failure were managed
medically.
All cases of cardiac death, heart failure and cardiac arrest
occurred in the general anaesthesia group, as well as six of the
sevenmyocardial infarctions. In total, 6.4% of patients in the general
anaesthesia group suffered one of these events, compared with .8%in the locoregional anaesthesia group (P ¼ 0.02). Asymptomatic
troponin release was observed in 6.9% of general anaesthesia
patients and 3.9% of locoregional anaesthesia patients (P ¼ 0.32).
Signiﬁcantly, more patients in the general anaesthesia group
suffered any cardiac event, compared with the locoregional
anaesthesia group (13.3% vs. 4.7%, P ¼ 0.02). An overview of all
cardiac events is presented in Table 2.
Multivariable propensity-adjusted regression analysis demon-
strated that general anaesthesia, compared with locoregional
anaesthesia, was associated with a signiﬁcantly increased risk of
any 30-day cardiac event (odds ratio (OR) 3.8; 95%-conﬁdence
interval (CI) 1.1e12.9; P ¼ 0.03), as well as with an increased risk of
‘major’ cardiac events, not including asymptomatic troponin
release (OR 13.3; 95%-CI 1.2e141.8, P ¼ 0.03).
Thirty-day non-cardiac events
In the study population, 39 major non-cardiac complications
occurred in 35 patients, of which 20 (11.6%) were in the general
anaesthesia group and 15 (11.6%) in the locoregional anaesthesia
group (P ¼ 1.00). Data are presented in Table 3.
Of the two non-cardiac deaths, one was caused by aspiration
and one by pneumonia. Non-fatal pulmonary complications
occurred in three patients, including two cases of pneumonia,
Table 3
30-day major non-cardiac complications.
General
(n ¼ 173)
Locoregional
(n ¼ 129)
P-value
n (%) n (%)
Non-cardiac complication
Non-cardiac complications 22 17
Patients with 1 complication 20 (11.6) 15 (11.6) 1.00
Mortality
All-cause 4 (2.3) 0 (0) .14
Non-cardiac 2 (1.2) 0 (0)
Pulmonary
Any pulmonary complication 5 (2.9) 0 (0) .07
Pneumonia 3 (1.7) 0 (0)
Aspiration 1 (.6) 0 (0)
Pneumothorax 1 (.6) 0 (0)
Renal
Renal failure requiring intervention 4 (2.3) 0 (0) .14
Surgical
Additional surgical procedure required 5 (2.9) 9 (7.0) .11
Intervention for endoleak 0 (0) 4 (3.1)
Access site bleeding 2 (1.2) 4 (3.1)
Arterial embolism 3 (1.7) 1 (.8)
Other
Urinary tract infection 2 (1.2) 2 (1.6)
Access site infection 1 (.6) 2 (1.6)
Urine retention 4 (2.3) 2 (1.6)
Sepsis 1 (.6) 1 (.8)
GI bleeding 0 (0) 1 (.8)
Stroke / TIA 0 (0) 0 (0)
Venous thrombo-embolism 0 (0) 0 (0)
Abbreviatons: GI gastro-intestinal; TIA transient ischaemic attack.
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with a chest tube. All pulmonary complications occurred in the
general anaesthesia group (2.9% vs. 0%, P ¼ 0.07).
Additional procedures for endoleak within 30 days of the
baseline procedure were required in four patients, all of whom
received locoregional anaesthesia for the index procedure. Addi-
tional surgery for access site bleeding was required by two patients
in the general anaesthesia group and four in the locoregional
anaesthesia group. Peripheral macroembolisation required embo-
lectomy or thrombolysis in three patients in the general anaes-
thesia group and one in the locoregional anaesthesia groups. In
total, ﬁve additional procedures were required in the general
anaesthesia group and nine in the locoregional anaesthesia group
(2.9% vs. 7.0%, P ¼ 0.11).
Major renal complications occurred in four patients, all of whom
were in the general anaesthesia group (2.3% vs. 0%, P ¼ 0.14). Of
these, two required permanent dialysis, one required a kidney
transplant and one required a percutaneous transluminal angio-
plasty (PTA) procedure of a renal artery due to trash nephropathy.
Discussion
Our data show a high risk of adverse cardiac events after EVAR
procedure, probably related to the presence of extensive co-
morbidity in the study population. This study demonstrates an
increased risk of cardiac complications after EVAR with general
anaesthesia, compared with locoregional anaesthesia, after adjust-
ing for cardiovascular co-morbidity, obesity and medication use.
The severity of the physiological stress response to surgery
depends on the invasiveness and length of the surgical procedure,
and its effects on haemodynamic stability, ﬂuid shifts, blood loss
and body temperature changes.10 The surgical stress response
causes tachycardia, increased myocardial contractility, systemic
inﬂammation, reduced ﬁbrinolytic activity, platelet activation and
consequent hypercoagulability.11 In the presence of coronary arterydisease, these changes may result in perioperative myocardial
infarction through either rupture of unstable coronary plaque and
subsequent coronary thrombosis, or prolonged myocardial oxygen
supply to demand mismatch.7
A coronary tree unaffected by atherosclerosis is present in only
8% of vascular surgery patients. These patients are at high risk of
perioperative cardiac events, with a peak incidence on the ﬁrst
postoperative days.12,13
The surgical stress response is more effectively attenuated by
locoregional anaesthesia, compared with general anaesthesia.14 It
was hypothesised that locoregional anaesthesia might improve
cardiac outcomes in major surgery patients. In a case-control study
of 88,188 patients, Wijeysundra demonstrates that epidural
anaesthesia is associated with a small but signiﬁcant reduction of
all-cause mortality after major surgery.15 In a meta-analysis of 30
trials which randomised for locoregional anaesthesia, Rodgers also
found a reduced risk of perioperative myocardial infarction (OR .67;
95%-CI .45e1.00).8
Previous studies indicate that the performance of EVAR is
feasible under multiple types of anaesthesia including general,
neuraxial and local anaesthesia.16,17 Analysis of the EUROpean
collaborators on Stent-graft Techniques for abdominal aortic
Aneurysm Repair (EUROSTAR) cohort of EVAR procedures indicates
that surgical outcomes (incidence of endoleaks) are similar for all
types of anaesthesia.18
No conclusive data exist regarding the relation between
anaesthesia type and cardiac outcome in EVAR. In the current
study, we observed a signiﬁcantly increased incidence of cardiac
events in the general anaesthesia group (OR 3.8). The CI is
compatible with both a very minor increase and a more than 10-
fold increase (95%-CI 1.1e12.9).
In a cohort study of 424 EVAR procedures by Parra (279 general,
95 regional and 50 local anaesthetics), cardiac event rates were 7%,
14% and 0% in the general, regional and local anaesthetic group,
respectively, with a statistically signiﬁcant difference between the
epidural and local anaesthetic group.9 No multivariable analysis,
adjusting for differences in baseline characteristics, was performed.
De Virgilio found no difference in cardiac events after EVAR between
general and local anaesthesia in a cohort of 229 patients.19 Analysis
of data from EUROSTAR suggests a reduced risk of cardiac events in
local (1%) and regional (2.9%), as comparedwith general anaesthesia
(3.7%). However, neither the deﬁnition of cardiac complications
nor the method used to score these complications was provided.18
Possible explanations of our results include differences in
surgical stress response attenuation, and in arterial perfusion due
to vasodilation induced by locoregional anaesthesia, although the
latter is unlikely due to the limited area of effect of both local
anaesthesia and lumbar epidural anaesthesia. In addition, differ-
ences in ﬂuid requirements between general and locoregional
anaesthesia might have inﬂuenced tissue perfusion due to hae-
modilution. Another factor of possible inﬂuence is the occurrence
of per- and postoperative hypoxaemia. Due to the retrospective
study design, we are unfortunately not able to provide adequate
data on this parameter.
We observed no difference in the non-cardiac complication rate
between general (11.6%) and locoregional (11.6%) anaesthesia
groups (P ¼ 1.00). However, general anaesthesia was associated
with a trend towards an increased risk of pulmonary complications
(2.9% vs. 0%, P ¼ 0.07) and increased length of stay. This is in
accordance with previous reports.20 A trend towards an increased
risk of the requirement for additional surgical procedures for
endoleak, access site bleeding or macro-embolisationwas observed
in the locoregional anaesthesia group (7.0% vs. 2.9%, P ¼ 0.11).
Study limitations include the retrospective cohort design,
because of which no causal relationship between anaesthesia type
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subject to selection bias. To reduce selection bias, we excluded
patients undergoing hybrid procedures, as well as patients under-
going emergency procedures, as both are likely to inﬂuence both
the choice of anaesthesia type and the risk of cardiac complications.
In addition, we used propensity-adjusted multivariable regression
analysis to adjust for co-morbidity, obesity and antiplatelet and
anticoagulant drug use, as these are also known to inﬂuence the
choice of anaesthesia technique. Possible factors inﬂuencing our
results are differences in surgical and anaesthetic management
over time, and a relatively small sample size. We decided to pool
local and regional anaesthesia, as both have been demonstrated to
effectively attenuate the surgical stress response, compared with
general anaesthesia. The study end point is a composite end point
including asymptomatic troponin release, as postoperative
asymptomatic troponin release is known to be highly predictive of
both short and long-term mortality.21 As many patients who suffer
postoperative troponin release do not experience any symptoms,
the cardiac event rate in this study is higher than in previous
studies of EVAR that did not include asymptomatic troponin release
in the study end points.
In conclusion, general anaesthesia, compared with locoregional
anaesthesia, is associated with an increased risk of cardiac events
after EVAR. Patient preferences, expected patient compliance,
procedure length and anatomical factors should be considered in
selection of anaesthesia type. However, when no contra-indications
are present, a locoregional anaesthesia technique might be favour-
able for EVAR. In our opinion, despite possible difﬁculties involved,
including the need for a very large sample size, as well as reluctance
from both surgeons and patients, a randomised trial of general and
locoregional anaesthesia techniques in elective EVAR is warranted.
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